Radiopharmaceuticals Market to grow at a CAGR of 9.12% during 2025 to 2035; Driven by Rising Prevalence of Cancer and Increasing Adoption of Nuclear Medicine for Diagnosis and Treatment

Radiopharmaceuticals Market Highlights

The Radiopharmaceuticals Market size was valued at USD 7.09 Billion in 2024 and the market is projected to grow from USD 7.737 Billion in 2025 to USD 18.52 Billion by 2035, exhibiting a CAGR of 9.12% during the forecast period 2025–2035.

The growth of the market is primarily driven by technological advancements in nuclear medicine, increasing demand for personalized and targeted therapies, and a rising incidence of cancer worldwide. Radiopharmaceuticals are increasingly used for both diagnostic and therapeutic purposes, particularly in oncology and cardiology.

Significant progress in artificial intelligence (AI) and radiochemistry has enhanced the precision and safety of nuclear imaging and therapy. The growing adoption of personalized medicine has also accelerated demand for tailored radiopharmaceutical solutions, enabling patient-specific treatment approaches.

Furthermore, supportive regulatory frameworks across major regions, including the U.S. FDA and European Medicines Agency (EMA), are streamlining approval pathways and encouraging innovation. The market is expected to see major investments in automated radiopharmaceutical production facilities and novel radiotracers for neurodegenerative diseases in the coming years.

Segment Analysis

The Global Radiopharmaceuticals Market has been segmented based on Type, Application, End Use, and Radiopharmaceutical Class.

The Type segment is bifurcated into Diagnostic Radiopharmaceuticals (largest) and Therapeutic Radiopharmaceuticals (fastest-growing). Diagnostic Radiopharmaceuticals applications currently dominate due to widespread use in imaging modalities like PET and SPECT, while therapeutic applications are expanding rapidly with a growing focus on oncology and targeted therapies.

The Application segment is bifurcated into Diagnosis, Therapy, and Research. The Diagnosis segment holds the largest share, driven by increased adoption in cancer and cardiovascular disease imaging. The Therapy segment, however, is expected to exhibit the highest growth due to advancements in radiotherapeutics and personalized medicine.

The Radiopharmaceutical Class segment is bifurcated into Radioisotopes (dominant) and Radiolabeled Compounds (emerging). Radioisotopes remain essential for both diagnostic and therapeutic purposes, while radiolabeled compounds are gaining traction in targeted therapy.

The End Use segment is bifurcated into Hospitals (largest), Diagnostic Imaging Centers (fastest-growing), and Research Institutions (emerging). Hospitals dominate due to extensive infrastructure for administering radiopharmaceuticals, while diagnostic imaging centers are expanding with the rise of outpatient diagnostic facilities.

Region Analysis

By Region, the Radiopharmaceuticals Market is segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. North America dominates the global market, accounting for around 45% of the total share. The region benefits from advanced healthcare infrastructure, a high prevalence of cancer, and supportive regulatory frameworks. The U.S. leads the market, with strong contributions from Cardinal Health, GE Healthcare, and Lantheus Medical Imaging.

Key Findings of the Study

• North America leads with 40% share, with United States contributing 32%, supported by advanced nuclear medicine infrastructure.
  


• Diagnostic radiopharmaceuticals hold 62% share, reflecting strong adoption in non-invasive imaging and disease identification technologies worldwide.
  


• Hospitals account for 52% share, driven by availability of advanced treatment facilities and growing demand for integrated diagnostic services.
  


• Diagnostic applications dominate with 58% share, driven by increasing demand for early disease detection and imaging procedures globally.